As of 2025-03-18, the Relative Valuation of Arbutus Biopharma Corp (ABUS) is (11.03) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.28 USD, the upside of Arbutus Biopharma Corp based on Relative Valuation is -436.3%.
The range of the Relative Valuation is (8.82) - (12.54) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.8x - 36.7x | 29.2x |
| Forward P/E multiples | 19.5x - 31.0x | 25.2x |
| Fair Price | (8.82) - (12.54) | (11.03) |
| Upside | -368.8% - -482.3% | -436.3% |
| Date | P/E |
| 2025-03-17 | -8.09 |
| 2025-03-14 | -8.15 |
| 2025-03-13 | -8.20 |
| 2025-03-12 | -7.88 |
| 2025-03-11 | -7.56 |
| 2025-03-10 | -7.68 |
| 2025-03-07 | -8.18 |
| 2025-03-06 | -8.33 |
| 2025-03-05 | -8.55 |
| 2025-03-04 | -8.38 |
| 2025-03-03 | -8.45 |
| 2025-02-28 | -8.52 |
| 2025-02-27 | -8.33 |
| 2025-02-26 | -8.50 |
| 2025-02-25 | -8.52 |
| 2025-02-24 | -8.25 |
| 2025-02-21 | -8.45 |
| 2025-02-20 | -8.50 |
| 2025-02-19 | -8.38 |
| 2025-02-18 | -8.30 |
| 2025-02-14 | -8.13 |
| 2025-02-13 | -8.15 |
| 2025-02-12 | -8.18 |
| 2025-02-11 | -8.18 |
| 2025-02-10 | -8.23 |
| 2025-02-07 | -8.47 |
| 2025-02-06 | -8.42 |
| 2025-02-05 | -8.87 |
| 2025-02-04 | -8.30 |
| 2025-02-03 | -8.10 |
| 2025-01-31 | -8.23 |
| 2025-01-30 | -8.15 |
| 2025-01-29 | -8.35 |
| 2025-01-28 | -8.28 |
| 2025-01-27 | -8.47 |
| 2025-01-24 | -8.20 |
| 2025-01-23 | -8.25 |
| 2025-01-22 | -7.96 |
| 2025-01-21 | -7.93 |
| 2025-01-17 | -7.91 |
| 2025-01-16 | -7.96 |
| 2025-01-15 | -8.10 |
| 2025-01-14 | -7.86 |
| 2025-01-13 | -8.28 |
| 2025-01-10 | -8.13 |
| 2025-01-08 | -8.28 |
| 2025-01-07 | -8.42 |
| 2025-01-06 | -8.08 |
| 2025-01-03 | -8.45 |
| 2025-01-02 | -8.13 |